PURPOSE: The treatment of @entity151 @entity1 with good performance status aims to improve survival. Dose-intensification could be a way to achieve improved survival but can be limited by @entity1398 and @entity882 . Preliminary, nonrandomized feasibility studies showed that @entity632 , @entity786 , and @entity2879 ( @entity1289 ) could be given every 2 (instead of the usual 3) weeks with @entity1261 ( @entity1261 ) (lenograstim; Chugai-Rh  one-Poulenc, Tokyo, Japan) support. The present multicenter randomized trial was designed to examine whether such dose-intensification improves survival while maintaining acceptable @entity137 levels. @entity1 AND METHODS: All @entity1 were randomized to receive six cycles of @entity1289 either every 3 weeks (control [C] group) or every 2 weeks with @entity1261 (G group). The standard dose-intensity of @entity1289 was increased by 50% in group G. RESULTS: Four hundred and three @entity1 (G group: n = 201; C group: n = 202) were randomized. The received dose-intensity was 34% higher in the G group than in the C group. Complete response rates were 40% for the G group and 28% for the C group (P =.02), and overall rates were 78% for the G group and 79% for the C group. Survival was longer in the G group (hazard ratio = 0.80; 95% confidence interval, 0.65 to 0.99; P =.04), survival rates for the G and C groups being 47% and 39% at 12 months and 13% and 8% at 24 months, respectively. @entity3 -free survival, nonhematologic @entity137 , and quality of life were similar in the two groups. In the G group, there was less @entity1398 but more @entity882 and more frequent blood and platelet transfusions. CONCLUSION: Increasing the dose-intensity of @entity1289 with @entity1261 support improved survival while maintaining acceptable @entity137 .

Improving survival without reducing quality of life in @entity151 @entity1 by increasing the dose-intensity of chemotherapy with XXXX support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1289 :: ('1636', 'Gene') :: ['ACE'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte colony-stimulating factor'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['Metastasis'] @entity151 :: ('MESH:D055752', 'Disease') :: ['small-cell lung cancer']
@entity1261 :: (1440,Gene) :: ['granulocyte colony-stimulating factor']
